The NZX achieved a significant milestone today, closing above 9000 points for the first time. We also saw Orion Healthcare jump 34% after shoring up their balance sheet. Ebos continued their upward trajectory after increasing their revenue by $1b. Synlait and a2 announced a new 5 year agreement.
We would like to introduce a new member to our adviser team. Jeremy Simpson has joined us after 8 years working as a Pensions Specialist for a large New Zealand financial planning firm. Jeremy has extensive expertise in the UK pension transfer market, having spent 4 years working in London for a UK pension provider. Jeremy moved to New Zealand in 1999 with his wife Dawn and now four children. They previously lived in Mount Pleasant until the earthquakes forced...
INTERNATIONAL EQUITY INVESTMENTS The UK Listed trusts manage diversified international share portfolios and reliant on the managers ability to navigate the global financial markets. These investments are listed on the London Stock Exchange denominated in Sterling. Below is a brief summary of the favoured investments trusts. Bankers Investment Trust provides a one-stop shop for global equity exposure. Its legacy was strongly UK-centric, but during current managers tenure more than 60% of the fund is now invested overseas. There is a...
MARKET CAP : $1.6 BILLION SECTOR - LOGISTICS EST. DIVIDEND YIELD (HISTORICAL): 3.2% PRICE - EARNINGS RATIO 23.5 PRICE/FAIR VALUE 0.82 Brambles are showing signs of life, following a change in leadership on the back of CEO Tom Gorman leaving in March last year. The past 12 months for Brambles can be summed up as a restructure and refocus. Graham Chipchase is well known for focusing on core operations and divesting of noncore assets that fail to provide a sufficient...
SECTOR - HEALTHCARE MARKET CAP 87,141 M AUD HISTORICAL DIV YIELD 1% P.A Investment Perspective CSL is one of three major players in the global blood-plasma-derived biotherapies space. We expect consistent product innovation to drive high-single-digit top-line growth in developed markets, augmented by mid-teen lower-margin sales growth in emerging markets. With moderate operating leverage, this should result in double-digit profit growth during the next few years. CSL is cost-competitive, given its manufacturing scale and a wide plasma-derived product range that...
MARKET CAP : $659M (@ $1.09 SP) NET TANGIBLE ASSETS (1H 18) :$0.81 PER SHARE ADJUSTED NTA PER SHARE: $1.01 PER SHARE (includes CBRE Ellis Value of existing sites and Work in Progress) EST. DIVIDEND YIELD : 4.5% The main reasons we like the stock are as follows: Relatively good yield (4.5%) for a company in this sector due to higher proportion of care beds. Good “brownfields” development opportunities within its existing portfolio. Shareholders with significant holdings will be looking...
MARKET CAP : $1,321M (@ $6.20 SP) NET TANGIBLE ASSETS (1H 18) :$6.63 PER SHARE EST. DIVIDEND YIELD : 1.5% Metlifecare is actually the longest listed aged healthcare stock on the NZX, having listed in 1994. It currently it operates more than 20 villages, located primarily in high-value and high-growth regions of New Zealand's upper North Island. Over the last year its share price is up only 12%, underperforming its listed peers Ryman and Summerset by 28% & 43% respectively....
Hamilton Hindin Greene’s Investment Committee consists of six committee members, combining a broad level of expertise which ensures our clients receive a robust investment service. The current sitting members include two independent members, three HHG advisers and one HHG director. The committee meet once a month, or as market movements dictate, to discuss the recommended portfolio and investigate avenues to bring further value to our clients. This allows Hamilton Hindin Greene in conjunction with its advisers to provide clients with an...
Seemingly not a day goes by where various “media commentators” espouse their opinion on the current level of the New Zealand share market, almost uniformly describing the market as overvalued. On the face of it, this seems perfectly reasonable, given the market is hitting all-time highs on a daily basis. But do these highs really represent a market that has outperformed? Detailed analysis tends to prove otherwise. The chart tracks the New Zealand share market since its highest point it hit...
For this weekend's feature business article in the New Zealand Herald, Jeremy Sullivan chats with Holly Ryan on the rise and fall of former market darling Orion Health. It had "huge growth potential", "elegant products", a share price that topped $6 and a market value of more than $1 billion. Fast forward to today, with the market value below $160 million and a share price that has been as low as 57c, and the question has to be asked: what went...
